Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Jan;69(1):191–195. doi: 10.1038/bjc.1994.33

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.

M T Seymour 1, J L Mansi 1, C J Gallagher 1, M E Gore 1, P G Harper 1, T R Evans 1, P M Edmonds 1, M L Slevin 1
PMCID: PMC1968773  PMID: 8286205

Abstract

This phase II study evaluates the efficacy and toxicity of a prolonged schedule of oral etoposide in patients with measurable advanced ovarian cancer resistant to, or relapsed following, platinum-based chemotherapy. Forty-seven patients participated, 20 of whom had received more than one prior treatment. Seventy-seven per cent had evidence of disease progression during or within 6 months of the previous chemotherapy. Initially, oral etoposide, 50 mg b.d. (regardless of patient size), was given for 14 days on a 21-day cycle. However, after encountering toxicity, the schedule was modified to 7 days' treatment escalating to 10 then 14 days if well tolerated. Among 41 assessable patients there were two complete and eight partial objective responses (24% response rate; 95% confidence interval 12-41%). Nine further patients (22%) had stable disease, four with a sustained fall of > 50% in CA-125. Median duration of response or stable disease was 35 weeks (range 21-49). Overall median survival was 41 weeks from study entry (range 2 to 96+ weeks). Toxicity for most patients was mild, but sporadic severe myelotoxicity occurred, with two treatment-related deaths. Risk factors for severe toxicity were: performance status 3; hepatic impairment; renal impairment. We conclude that oral etoposide has activity in platinum-resistant ovarian cancer and that it is a useful palliative therapy. It has significant toxicity which may be avoided by appropriate patient selection and an escalating-duration schedule.

Full text

PDF
191

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belinson J. L., Pretorius R. G., McClure M., Ashikaga T. Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies. Gynecol Oncol. 1986 Mar;23(3):304–309. doi: 10.1016/0090-8258(86)90130-7. [DOI] [PubMed] [Google Scholar]
  2. Benedetti Panici P., Scambia G., Greggi S., Salerno G., Cento R., Mancuso S. Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy. Oncology. 1990;47(4):296–298. doi: 10.1159/000226836. [DOI] [PubMed] [Google Scholar]
  3. Coleman R., Clarke J., Gore M., Wiltshaw E., Slevin M., Harper P. A phase II study of mitozantrone in advanced carcinoma of the ovary. Cancer Chemother Pharmacol. 1989;24(3):200–202. doi: 10.1007/BF00300244. [DOI] [PubMed] [Google Scholar]
  4. Coleman R., Towlson K., Wiltshaw E., Slevin M., Blake P., Stein R., Coombes R., Harper P. Epirubicin for pretreated advanced ovarian cancer. Eur J Cancer. 1990;26(7):850–851. doi: 10.1016/0277-5379(90)90173-q. [DOI] [PubMed] [Google Scholar]
  5. Eckhardt S., Hernádi Z., Thurzó L., Telekes A., Sopkova B., Mechl Z., Pawlicki M., Kerpel-Fronius S. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study. Oncology. 1990;47(4):289–295. doi: 10.1159/000226835. [DOI] [PubMed] [Google Scholar]
  6. Einzig A. I., Wiernik P. H., Sasloff J., Runowicz C. D., Goldberg G. L. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol. 1992 Nov;10(11):1748–1753. doi: 10.1200/JCO.1992.10.11.1748. [DOI] [PubMed] [Google Scholar]
  7. Greco F. A., Johnson D. H., Hainsworth J. D. Chronic daily administration of oral etoposide. Semin Oncol. 1990 Feb;17(1 Suppl 2):71–74. [PubMed] [Google Scholar]
  8. Hansen F., Malthe I., Krog H. Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer. Gynecol Oncol. 1990 Mar;36(3):369–370. doi: 10.1016/0090-8258(90)90144-a. [DOI] [PubMed] [Google Scholar]
  9. Harvey V. J., Slevin M. L., Joel S. P., Smythe M. M., Johnston A., Wrigley P. F. Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol. 1985 Nov;21(11):1315–1319. doi: 10.1016/0277-5379(85)90310-4. [DOI] [PubMed] [Google Scholar]
  10. Hill B. T., Whelan R. D., Rupniak H. T., Dennis L. Y., Rosholt M. A. A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Pharmacol. 1981;7(1):21–26. doi: 10.1007/BF00258208. [DOI] [PubMed] [Google Scholar]
  11. Hillcoat B. L., Campbell J. J., Pepperell R., Quinn M. A., Bishop J. F., Day A. Phase II trial of VP-16-213 in advanced ovarian carcinoma. Gynecol Oncol. 1985 Oct;22(2):162–166. doi: 10.1016/0090-8258(85)90022-8. [DOI] [PubMed] [Google Scholar]
  12. Lee C. R., Nicholson P. W., Souhami R. L., Slevin M. L., Hall M. R., Deshmukh A. A. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer. 1993 Mar;67(3):630–634. doi: 10.1038/bjc.1993.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Manetta A., MacNeill C., Lyter J. A., Scheffler B., Podczaski E. S., Larson J. E., Schein P. Hexamethylmelamine as a single second-line agent in ovarian cancer. Gynecol Oncol. 1990 Jan;36(1):93–96. doi: 10.1016/0090-8258(90)90115-2. [DOI] [PubMed] [Google Scholar]
  14. Marzola M., Zucchetti M., Colombo N., Sessa C., Pagani O., D'Incalci M., Cavalli F., Mangioni C. Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol. 1993 Jun;4(6):517–519. doi: 10.1093/oxfordjournals.annonc.a058565. [DOI] [PubMed] [Google Scholar]
  15. McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
  16. Miller J. C., Einhorn L. H. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol. 1990 Feb;17(1 Suppl 2):36–39. [PubMed] [Google Scholar]
  17. Pater J. L., Carmichael J. A., Krepart G. V., Fraser R. C., Roy M., Kirk M. E., Levitt M., Brown L. B., Wilson K. S., Shelley W. E. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treat Rep. 1987 Mar;71(3):277–281. [PubMed] [Google Scholar]
  18. Slevin M. L., Clark P. I., Joel S. P., Malik S., Osborne R. J., Gregory W. M., Lowe D. G., Reznek R. H., Wrigley P. F. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol. 1989 Sep;7(9):1333–1340. doi: 10.1200/JCO.1989.7.9.1333. [DOI] [PubMed] [Google Scholar]
  19. Slevin M. L. Low-dose oral etoposide: a new role for an old drug? J Clin Oncol. 1990 Oct;8(10):1607–1609. doi: 10.1200/JCO.1990.8.10.1607. [DOI] [PubMed] [Google Scholar]
  20. Sutton G. P., Blessing J. A., Homesley H. D., Berman M. L., Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1989 Nov;7(11):1672–1676. doi: 10.1200/JCO.1989.7.11.1672. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES